Dalkhimpharm reported for 2025 under RAS

Dalkhimpharm's RAS net profit for 2025 amounted to ₽343.3 million, an increase of 39.2% compared to ₽246.6 million in the previous year. Revenue increased by 10.3% to ₽3.75 billion, compared to ₽3.4 billion a year earlier.